Form 4: Teva Pharma Exec's Equity Activity

Teva Pharmaceutical Industries' EVP, U.S. Commercial, Christine Fox, reported RSU vesting, a tax-related share sale, and a new RSU grant.

Summary

• Christine Fox, EVP, U.S. Commercial of Teva Pharmaceutical Industries Ltd. (TEVA), reported transactions on March 4, 2026.
• Acquired 20,461 Ordinary Shares upon the vesting of Restricted Share Units (RSUs).
• Disposed of 9,098 Ordinary Shares at a weighted average price of $32.4645 to cover tax withholding obligations related to the RSU vesting.
• The share disposition was executed pursuant to a Rule 10b5-1 trading plan adopted on August 11, 2025.
• Received a new grant of 50,643 Restricted Share Units.
• Following these transactions, Christine Fox beneficially owns 75,010 Ordinary Shares directly and 91,566 derivative securities (RSUs) directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, representing routine executive compensation activity and tax-related share dispositions, which are common and pre-planned.

Positives

• The grant of 50,643 new Restricted Share Units aligns executive incentives with long-term shareholder value.
• The vesting of 20,461 Restricted Share Units represents a successful realization of previously granted equity compensation.

Negatives

• The disposition of 9,098 Ordinary Shares, even for tax purposes, reduces the executive's direct equity ownership in the company.

Future Outlook

Future vesting schedules for Restricted Share Units indicate continued equity compensation for the executive, with 20,461 RSUs vesting on March 4, 2027, 20,462 on March 4, 2028 (from previous grants), and new grants vesting with 12,660 on March 4, 2027, March 4, 2028, March 4, 2029, and 12,663 on March 4, 2030.

Industry Context

StockSavvy.ai notes that executive equity compensation, including Restricted Share Units and subsequent tax-related share sales under Rule 10b5-1 plans, is a standard practice across the pharmaceutical industry. This mechanism is widely used to align executive interests with long-term shareholder value while providing a structured approach to insider trading compliance.

Comparison to Industry Standards

• Executive compensation structures involving multi-year RSU vesting schedules are standard practice among large pharmaceutical companies, comparable to those at peers like Pfizer Inc. or Johnson & Johnson, which also utilize such plans to retain talent and incentivize performance.
• The use of a Rule 10b5-1 trading plan for share dispositions, particularly for tax withholding, is a common and accepted compliance measure for executives across all major public companies, ensuring transactions are pre-planned and not based on material non-public information.

Stakeholder Impact

• Shareholders: Minimal impact as these are routine executive compensation and tax-related transactions, not indicative of fundamental company changes.
• Employees: Reflects standard executive compensation practices within the company.

Next Steps

• Future vesting of 20,461 Restricted Share Units on March 4, 2027.
• Future vesting of 20,462 Restricted Share Units on March 4, 2028.
• Future vesting of 12,660 new Restricted Share Units on March 4, 2027.
• Future vesting of 12,660 new Restricted Share Units on March 4, 2028.
• Future vesting of 12,660 new Restricted Share Units on March 4, 2029.
• Future vesting of 12,663 new Restricted Share Units on March 4, 2030.

Key Dates

Recommendation

The filing details routine executive compensation activities, including RSU vesting and a tax-related share sale under a pre-established 10b5-1 plan. These transactions do not indicate a change in the company's fundamental outlook or performance, thus a 'hold' recommendation is appropriate as there's no new information to warrant a change in investment thesis.

Keywords

Teva Pharmaceutical Industries, TEVA, Christine Fox, Form 4, Insider Transaction, Restricted Share Units, RSU, Equity Compensation, 10b5-1 Plan, Executive Compensation